Omnicell (NASDAQ:OMCL) Hits New 12-Month High – What’s Next?

Omnicell, Inc. (NASDAQ:OMCL)’s share price hit a new 52-week high on Wednesday . The company traded as high as $47.79 and last traded at $47.4350, with a volume of 110807 shares. The stock had previously closed at $47.07.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Benchmark boosted their price objective on Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 9th. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 target price on the stock in a research report on Wednesday. Weiss Ratings reissued a “sell (d+)” rating on shares of Omnicell in a report on Wednesday, October 8th. Finally, Wells Fargo & Company raised their price target on shares of Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research report on Monday. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $47.83.

Omnicell Stock Up 6.6%

The company has a current ratio of 1.44, a quick ratio of 1.21 and a debt-to-equity ratio of 0.14. The business’s fifty day moving average price is $40.72 and its 200 day moving average price is $34.09. The company has a market capitalization of $2.27 billion, a P/E ratio of 117.65, a P/E/G ratio of 4.89 and a beta of 0.77.

Institutional Investors Weigh In On Omnicell

Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC increased its position in shares of Omnicell by 6.6% during the 3rd quarter. SG Americas Securities LLC now owns 6,433 shares of the company’s stock worth $196,000 after purchasing an additional 401 shares in the last quarter. Thrivent Financial for Lutherans grew its position in Omnicell by 1.2% during the 2nd quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock worth $1,013,000 after acquiring an additional 424 shares during the last quarter. Martin & Co. Inc. TN grew its position in Omnicell by 0.4% during the 3rd quarter. Martin & Co. Inc. TN now owns 121,720 shares of the company’s stock worth $3,706,000 after acquiring an additional 443 shares during the last quarter. Legal & General Group Plc increased its holdings in Omnicell by 0.3% during the 3rd quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock valued at $4,823,000 after purchasing an additional 448 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Omnicell by 37.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock valued at $50,000 after purchasing an additional 458 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.